Josh Abbott

2 weeks ago | bioprocessintl.com | James Choi |Josh Abbott |Shreeyashi Ojha |Dan Stanton

Planning for commercial biologic manufacturing is challenging, not least because it requires considerable time, investment, and economic risk. As global demand for biopharmaceuticals climbs, drug companies will need to be resourceful to ensure that their products will be manufactured at sufficient volumes and in the desired markets. This eBook places bioproduction capacity in the spotlight, highlighting options that biologics developers can leverage as they seek to expand their global reach.

3 weeks ago | bioprocessintl.com | Dan Stanton |Josh Abbott

Imunon looks to DNA vaccine tech to support ovarian cancer immunotherapyDepositPhotos/drecunThe New Jersey-based biotech is developing non-viral DNA technology for various modalities. Its lead candidate is IMNN-001, an immunotherapy for ovarian cancer, based on the firm’s TheraPlas platform.

Feb 18, 2025 | bioprocessintl.com | Josh Abbott |Shreeyashi Ojha

In a 53-47 vote that fell entirely across party lines, Robert F. Kennedy Jr. was confirmed by the US Senate to lead the Department of Health and Human Services as secretary. Ultimately, the few Republican senators such as Bill Cassidy (R-LA), who had expressed skepticism in President Donald Trump’s pick, fell in line, making official the result that analysts expected.

Jan 15, 2025 | bioprocessintl.com | Josh Abbott

Samarth Kulkarni, CEO of CRISPR Therapeutics, spoke at the JP Morgan Healthcare Conference about his firm’s development of allogeneic therapies and their manufacturing and cost advantages compared with autologous therapies.

Jan 10, 2025 | bioprocessintl.com | Josh Abbott

Contract development and manufacturing organization (CDMO) Samsung Biologics extended its partnership with Korea-based biopharmaceutical development firm LigaChem Biosciences to provide antibody-drug conjugate (ADC) services. The extension stems from an agreement first signed by the two companies in February 2024. A spokesperson for Samsung Biologics told BioProcess Insider that the companies will collaborate on three projects for the development of ADC therapies.